Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8786233 | Clinical Oncology | 2018 | 7 Pages |
Abstract
Adjuvant endocrine therapy use fell to 50% by 5 years, limiting possible survival benefits, providing support for efforts to increase compliance.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
B. Robinson, B. Dijkstra, V. Davey, S. Tomlinson, C. Frampton,